Abbott, Novo Nordisk seek to eliminate ‘hassle’

 - 
Wednesday, February 20, 2019

ABBOTT PARK, Ill. – Abbott and Novo Nordisk have partnered to integrate insulin dose data from Novo Nordisk’s connected insulin pens with digital health tools compatible with Abbot’s FreeStyle Libre continuous glucose monitoring system. The integration will allow healthcare professionals, caregivers and patients to view glucose and insulin data together to help them make better informed treatment decisions, according to a press release. "It is our aim at Abbott to continuously provide life-changing technology to people living with diabetes," said Jared Watkin, senior vice president, Diabetes Care, Abbott. “By enabling insulin dosing data from Novo Nordisk′s connected pens to be shared with our digital health tools, we′ll be able to help further eliminate those daily hassles for people, so they have more time to live a fuller, healthier life."